News
Is it time for universal genetic testing in colorectal cancer?
- Author:
- Mark L. Fuerst
A new study supports multigene panel testing for all colorectal cancer patients.
News
SNP chips deemed ‘extremely unreliable’ for identifying rare variants
- Author:
- Mark L. Fuerst
Single-nucleotide polymorphism chips are more likely to be wrong than right when it comes to rare variants, researchers say.
Article
ASCO, CSCO outline ‘best practices’ for nasopharyngeal carcinoma
- Author:
- Mark L. Fuerst
Experts mined studies in nasopharyngeal carcinoma to create new guidelines.
News
ASCO announces new advanced liver cancer guidelines
- Author:
- Mark L. Fuerst
The American Society of Clinical Oncology announced new guidelines for systemic therapy of advanced hepatocellular carcinoma.
News
Model could reduce some disparities in lung cancer screening
- Author:
- Mark L. Fuerst
Adding risk prediction to guidelines could help reduce some disparities in lung cancer screening.
News
Customized chemotherapy did not improve survival in early NSCLC
- Author:
- Mark L. Fuerst
Toxicity was less common with customized therapy.
News
Cisplatin tops cetuximab for advanced head and neck cancer
- Author:
- Mark L. Fuerst
Concurrent cisplatin should remain the standard treatment over cetuximab for patients with locoregionally...
News
Neoadjuvant atezolizumab safe for patients with resectable lung cancer
- Author:
- Mark L. Fuerst
Neoadjuvant atezolizumab was deemed “effective, well tolerated, and surgically acceptable.”
News
Sotorasib in NSCLC: ‘Historic milestone’ reached
- Author:
- Mark L. Fuerst
Phase 2 results with sotorasib support phase 1 results reported last year.
News
Death rates ‘remain high’ in patients with thoracic cancers and COVID-19
- Author:
- Mark L. Fuerst
The risk of death was similar across racial and ethnic groups.
News
Pandemic seems to impact lung cancer diagnosis and prognosis
- Author:
- Mark L. Fuerst
There was a 38% decrease in new lung cancer diagnoses during the pandemic, and 30-day mortality rates nearly doubled.
News
Nulliparity, not ART, likely raises risk of ovarian cancer
- Author:
- Mark L. Fuerst
A large study suggests that assisted reproductive technology procedures don’t raise risk of ovarian cancer....
News
Dexamethasone may ‘jeopardize’ benefit of immunotherapy in glioblastoma
- Author:
- Mark L. Fuerst
Baseline dexamethasone use was the strongest predictor of poor survival in glioblastoma patients receiving a checkpoint inhibitor.
News
Fear of recurrence highly prevalent in RCC survivors
- Author:
- Mark L. Fuerst
About 55% of survivors surveyed expressed fear of renal cell carcinoma recurrence.
News
Black patients with ES-SCLC get less chemo but have better survival
- Author:
- Mark L. Fuerst
A real-world analysis revealed racial and socioeconomic factors impacting systemic therapy delivery and survival...